This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nelson, L. A. Articles by Abu-Shanab, J. R. Search for Related Content Social Bookmarking                         What's this?

Management of Depression in Patients with Comorbid Cardiovascular Disease

St. Louis College of Pharmacy, Division of Pharmacy Practice, 4588 Parkview Place, St. Louis, MO 63110 and Assistant Professor of Psychiatry, Saint Louis University School of Medicine.lnelson{at}stlcop.edu

Joy R. Abu-Shanab

St. Louis College of Pharmacy, Division of Pharmacy Practice, 4588 ParkviewPlace, St. Louis, MO63110.

Evidence suggests that depression commonly occurs in patients with cardiovascular disease and is associated with a poor prognosis including increased risk of cardiac mortality. Proposed pathophysiologic mechanisms include decreased heart rate variability, altered sympathetic and parasympathetic activity, increased ventricular instability, and abnormal platelet reactivity. Other proposed mechanisms involve the interference of depression with medication adherence and cardiac risk factor reduction. Despite this evidence, depression during cardiovascular disease is commonly unrecognized and inadequately treated. Tricyclic antidepressants (TCA) are efficacious for treating depression in this population but cause serious cardiac side effects and should be avoided in patients with significant cardiovascular disease. More recent studies with bupropion and the selective serotonin reuptake inhibitors (fluoxetine, paroxetine, sertraline) indicate that they are acceptable alternatives to TCAs with regard to cardiac risk in depressed patients with heart disease, although larger studies are needed to validate their safety and efficacy in this special population. There are 3 studies currently being conducted to investigate the effect of antidepressant therapy and/or psychotherapy on cardiac morbidity and mortality in post–myocardial infarction patients with depression and/or low social support. These studies will hopefully answer the long-posed question of whether appropriate treatment of depression can improve cardiac prognosis.

Key Words: depression • antidepressants • cardiovascular disease

Journal of Pharmacy Practice, Vol. 14, No. 6, 526-539 (2001)
DOI: 10.1177/089719001129040874


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?